TFP_ Show Notes • Episode #005 • Nick Norwitz, PhD • Part 2

Brian Johnson under scrutiny, the carbohydrate-insulin model explained, and why the Kevin Hall Nature Medicine trial should be evaluated with a more critical lens.

Bryan Johnson: the $2M longevity experiment under scrutiny [0:49]

• Nick has been reviewing Brian Johnson’s long-form podcast appearances ahead of an interview for a video by YouTuber Joseph Everett, who has been doing substantive critical analysis of some of Johnson’s claims. Nick said yes to the interview and wanted to do his due diligence first.

• His high-level take on Johnson is genuinely positive. He finds him thoughtful in long form — the Trevor Noah podcast, the Derek MPMD episode, and Diary of a CEO with Steven Bartlett all show a man who has thought seriously about philosophy, social norms, and what society looks like in 50 to 100 years. “Of the longevity quote gurus in this space, he is my favorite overall. I actually think I like the guy.”

• Where Nick’s assessment becomes critical: the short-form content is less intellectually rigorous. He acknowledges the same could be said of himself — he hates doing Instagram reels, hates chopping long-form content into clips, knows short-form necessarily strips nuance. He tries to give Johnson the benefit of the doubt that short-form engagement bait is a deliberate strategy to drive people toward deeper material.

• The extraordinary claim that creates the problem: Johnson claims to be the healthiest person on the planet. Nick’s immediate instinct: you are going to feel very compelled to keep backing that up. Does he share when he gets a cold? When he has stomach flu or food poisoning? Or do those events simply not appear in the content, as though they don’t occur? That selective disclosure pattern concerns Nick in any influencer using their body as an advertisement for what they are promoting.

• Specific transparency issues Nick found while preparing for the Joseph Everett interview:

◦ Johnson has not released his LH and FSH levels, raising unanswered questions about whether he is still on testosterone.

◦ There was a period where he did not report an ApoB value, attributed to a measurement issue that Nick found unexplained.

◦ He published an Excel sheet claiming top-percentile status on various metrics. Nick checked the omega-3 index: Johnson reported 9.98% and claimed top 1%. Nick’s own omega-3 index is 17.2. If Johnson is in the top 1% at 9.98, what is Nick in? The reference range cited was not provided.

◦ Telomere length claims: claiming top 1% improvement in telomere length after a couple of years is, Nick says, implausible given what we know about telomerase activity. Supplementing high-dose NMN to raise intracellular NAD and then claiming youthful NAD levels is roughly analogous to a 9-year-old heavily supplementing zinc and claiming the zinc levels of an 18-year-old.

• Nick’s summary: “He’s clearly a healthy person overall. The labs, if you take them at face value, are fine. But the claim about being the healthiest person alive and some of the specifics about the percentiles he’s in, I think it could be done more rigorously.”

• His advice to Johnson, offered respectfully: up the scientific rigor and the optics around that rigor. Maybe everything behind the scenes is pristine and watertight. But when you go on Diary of a CEO and visibly do not know the details of the study you are citing, and then wave toward a team whose work is not accessible, you understand why people are skeptical. That is his Achilles heel.

The red meat thread: what is your single most compelling biological mechanism? [14:19]

• Johnson posted a thread about why he does not consume red meat and why he believes it would lower his longevity. He framed it carefully — I don’t eat it, but I’m fine if you do — rather than ideological condemnation. Nick acknowledges this. But the thread walked through epidemiological studies, and Nick had to bring up healthy user bias.

• His point: until recently, health-conscious people who proactively chose to eat red meat were essentially non-existent as a population. The people eating red meat in observational data tended to be more likely to smoke, less likely to exercise, and less likely to follow other health recommendations. We do not yet have a population of deliberately health-conscious carnivores large enough and old enough to disentangle that bias from the outcome data.

• Johnson conceded in the exchange that it is difficult to disentangle, but maintained he knows enough to hold his position. Nick finds this unsatisfying.

• Nick pared his response down to a single question and put it publicly: what is your single most compelling biological mechanism for why red meat is bad for longevity? Not a shadow-of-a-doubt answer. Just one decent biological rationale. Give me the best paper, the best experiment, the most compelling thing. Not IGF-1. Not TMAO. Not saturated fat. He has yet to find one that is compelling, and Johnson did not answer.

• He is explicit that he is not claiming animal-rich or carnivore diets are best for longevity. He is asking for the case to be supported before it is asserted. He adds: if Johnson hears this, he hopes he responds. “Maybe he didn’t see it. If he hears us now I hope he does respond to that.”

Lean mass hyperresponders and cardiovascular risk: where does the evidence actually sit? [24:21]

• Dave puts a direct question to Nick: if you give me a dataset of 1,000 lean mass hyperresponders with no other information about their lipid profile, where do they rank on cardiovascular risk on a 1–5 quintile scale?

• Nick’s answer: 1.25. Second quintile. He is hedging, partly because there is data he knows that has not yet been publicly released, and he is trying to answer naively to that.

• The key tension he surfaces: the LMHR study at Lundquist specifically excluded individuals with any prior cardiovascular disease, metabolic syndrome criteria, or a diagnosis of FH. The point was to isolate LDL as a variable in people who have none of the usual co-variables. Nick’s framing for the clinical question this raises: if a patient walked in meeting this eligibility criteria, would you tell them to take steps to lower their LDL? His answer: get functional imaging first. Get a coronary CT angiography. Because in the absence of detectable plaque, the current evidence does not support the conclusion that intervention to lower LDL will improve outcomes.

• He is careful about how he frames this: it is an absence of evidence position. Not evidence of absence. And he is comfortable defending that statement. Even in the familial hypercholesterolemia literature, if your CAC score is zero — and probably CTA because it has better resolution — your risk profile is pretty low regardless of LDL level.

• He discloses his own numbers: his LDL runs over 500. He is not medicated. His mother, approaching 60, has had elevated LDL her entire adult life, probably averaging in the 180 range before going keto, and has been a lean mass hyperresponder on top of that since. Her estimated cumulative LDL-years exposure is approaching 10,000 mg/dL-years. She just got a CCTA. Zero. Dave’s reaction: what do you do with that? Nick’s answer: she as an MD-PhD decided not to treat. Objectively, given zero plaque at that exposure burden, the answer is no.

• Nick describes a position he sees consolidating among a growing number of clinicians: high LDL on keto, next step imaging. If imaging shows low to zero risk, there currently is no data supporting action to lower LDL. In fact, there is quite a lot of data suggesting no benefit from treatment if CAC is already zero. The same clinicians would say: if you have existing cardiovascular disease or poor metabolic health, those factors change the calculus, and treatment may well be warranted depending on the degree of both.

• Dave notes that Brett Sher, a cardiologist who presented at COI, walked through exactly this risk-to-reward analysis and concluded there is probably no benefit and he would not prescribe in these cases. And Brett himself takes a statin. As does Adrian. These are not anti-statin people; they are pro-data people.

The residency decision explained in full [35:12]

• Dave sets the context for listeners who may not know: for medical students finishing their MD, the default next step is to apply for residency, a competitive matching process into a specialty. It is so culturally baked into the path that the icebreaker at the start of every Harvard medical school course is not “what are you doing next year?” but “what are you applying to for residency?”

• The residency path Nick would most likely have taken: pediatric endocrinology. He loves kids, has a genuine kid-energy in clinical settings, and could see himself being excellent with pediatric patients. That was the plan. For most of his life, it was the only plan.

• Why he stepped off it: he made the decision about seven months before this recording, after a long deliberation that involved talking to his parents, contacts of his parents, and senior people in his network. The core of it: the opportunity cost had become too large. Projects and relationships were coming together at a pace and scale that would require giving up if he committed to five or more years of residency and fellowship. And he was honest with himself that his mind was elsewhere. He would be sitting in a sub-internship writing patient notes and thinking about a paper he wanted to communicate. Not about the patient in front of him. That is not fair to the patient, and it is not fair to a peer who could take that residency spot and actually commit to it.

• “I think I would have been a fine doctor. I don’t think it was my calling.” Saying that out loud, he acknowledges, required confronting a version of shame — because you do not put in that many years and that much effort toward a goal without some level of identity being built around it. He calls it the easy hard choice: the track was already laid, it was hard to complete it, but the easy decision was to stay on the track that was laid before you. The hard hard choice was to step off it entirely for something with no clear path.

• The financial logic: income security is higher in medicine, but the ceiling is dramatically lower. He is transparent that he can see a future where the platform he is building funds not just a comfortable life but the $100 million metabolic health research and rehabilitation center he wants to create. That kind of funding does not come from NIH grants for carnivore versus vegan IBD RCTs. It comes from networks and philanthropists that social media access opens.

• Dave’s perspective on when he saw it becoming inevitable: the Oreo versus statin experiment. He describes watching the level of dedication Nick brought to broadcasting and amplifying that work and concluding: this guy should be doing this. He was cautious about being a bad influence. He stopped being cautious.

The 720 eggs experiment and what makes a good N=1 [56:47]

• The egg experiment — eating two dozen eggs per day for a period — turned out to be the most socially fruitful experiment Nick has done and physically the easiest. He could do it again right now without distress. Two large omelettes per day. Not unpleasant.

• The cross-platform viral reach was extraordinary. He was getting screenshots showing 143 million hits on TikTok. He is not on TikTok. Someone had taken his Daily Mail coverage and it had propagated across the platform without him. Vital Farms offered him a year of free eggs after the fact. He is now, as he puts it, bought off by Big Egg. He is also, as of the recording, having to buy his own eggs because the 2025 token renewal has not come through yet during the bird flu egg shortage.

• What makes N=1 experiments particularly valuable in his view: if the experiment is planned in advance and has a defined end date, you get a clean signal that you cannot get from naturalistic dietary changes, which are almost always confounded by the reason for the change — stress, life events, holidays, relationship disruptions. When Nick goes off diet by design for a study, he knows the dietary change is the only variable that shifted. The signal is crisp.

• Some experiments have been easy. Some have wrecked him. The 720 eggs were fine. The Oreo versus statin period was not — he was bouncing off the walls, which was partly documented by a photo Chris had from his YouTube where Nick’s hair was visibly dishevelled mid-COI announcement.